Endocyte Inc. (ECYT) was among the biggest gainers on the Russell 2000 for August 29 as the stock popped 5.44% to $7.36, representing a gain of $0.38 per share. Some 2,087,599 shares traded hands on 7,168 trades, compared with an average daily volume of 881,062 shares out of a total float of 41,550,956. The stock opened at $7.08 and traded with an intraday range of $7.04 to $7.48.
After today's gains, Endocyte Inc. reached a market cap of $305,810,881. Endocyte Inc. has had a trading range between $33.70 and $5.91 over the last year, and it had a 50-day SMA of $6.51 and a 200-day SMA of $11.14.
The stock has a P/E Ratio of 25.90.
Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases.
Endocyte Inc. is based out of West Lafayette, IN and has some 91 employees. It's CEO is P. Ellis.
For a full analysis of Endocyte Inc., check out Equities.com's E.V.A. report.
The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.
For more news on the financial markets, go to Equities.com. Also, learn more about our Small-Cap Stars. Register to become a member and leverage our proprietary research tools such as the Small-Cap Stars, and robust do-it-yourself Equities Valuation Analysis (E.V.A.) research reports.
All data provided by QuoteMedia and was accurate as of 4:30PM ET.